文献速递头痛与眩晕

唾液CGRP与依瑞奈尤单抗治疗反应:迈向偏头痛精准医学

Salivary CGRP and Erenumab Treatment Response: Towards Precision Medicine in Migraine.
PubMed 文献 · Ann Neurol · 2022-08-24

这项前瞻性观察研究测量健康对照、发作性偏头痛和慢性偏头痛患者的唾液CGRP水平,并评估依瑞奈尤单抗治疗后的变化。基线头痛频率越高CGRP越高,伴抑郁症状者更高;唾液CGRP可区分偏头痛与对照,且基线CGRP较高与发作性偏头痛患者50%以上头痛频率下降的概率相关,慢性偏头痛中未见此关联。

要点

  • 基线头痛频率越高,唾液CGRP水平越高,伴抑郁症状者更高。
  • 唾液CGRP区分偏头痛与对照的切点为103.93 pg/ml,AUC为0.801。
  • 基线唾液CGRP较高与发作性偏头痛患者50%以上头痛频率下降的概率相关,慢性偏头痛中未见。

核心结论

  • 偏头痛患者唾液CGRP水平高于健康对照,抑郁症状似乎会升高唾液CGRP水平。
  • 首次提供证据表明基线唾液CGRP浓度与依瑞奈尤单抗治疗反应相关。

研究设计与样本

  • 前瞻性观察研究,测量健康对照、发作性偏头痛和慢性偏头痛患者的唾液CGRP水平。
  • 受试者在基线采集唾液,拟接受依瑞奈尤单抗治疗的患者在3剂治疗后再次采集唾液。
  • 采用酶联免疫吸附试验(ELISA)定量CGRP样免疫反应性,并通过广义线性混合模型分析基线与治疗后数据。

主要发现

  • 基线时头痛频率越高与CGRP水平越高相关,伴抑郁症状时CGRP水平更高。
  • 区分偏头痛与对照的切点为103.93 pg/ml(95%CI 103.35-104.51),受试者工作特征曲线下面积(AUC)为0.801(95%CI 0.798-0.804)。
  • 基线唾液CGRP较高与发作性偏头痛患者达到50%以上头痛频率下降的概率统计学显著相关,慢性偏头痛患者中未见此关联。
  • 依瑞奈尤单抗治疗12周后,全偏头痛频率谱患者的唾液CGRP水平趋同至相似值;伴抑郁症状者未出现此趋同。

关键数值与推荐

  • 唾液CGRP区分偏头痛与对照的切点为103.93 pg/ml(95%CI 103.35-104.51),AUC为0.801(95%CI 0.798-0.804)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed (1) to analyze salivary calcitonin gene-related peptide (CGRP) levels in patients with migraine, (2) to predict erenumab response from baseline CGRP levels, and (3) to evaluate CGRP change post-treatment. METHODS: This is a prospective observational study that measured salivary CGRP levels in healthy controls (HCs), patients with episodic migraine (EM) and patients with chronic migraine (CM). Participants collected saliva samples at baseline and, the patients who were candidates to receive erenumab, also collected saliva after 3 doses of treatment. We quantified CGRP-like immunoreactivity (CGRP-LI) by enzyme-linked immunosorbent assay (ELISA) and we performed an analysis at baseline and post-treatment through generalized linear mixed models. RESULTS: At baseline, a higher headache frequency was associated with higher CGRP levels, those being even higher in the presence of depressive symptoms. A cutoff point (mean, 95% confidence interval [CI]) of 103.93 (95% CI = 103.35-104.51) pg/ml was estimated to differentiate migraine from controls with an area under the receiver operating characteristic (ROC) curve (AUC, 95% CI) of 0.801 (95% CI = 0.798-0.804). We also found that higher pretreatment salivary CGRP levels were statistically significantly associated to a higher probability of having 50% or greater reduction in headache frequency in patients with EM, but not in patients with CM. After 12 weeks of treatment with erenumab, salivary CGRP levels from patients within all spectrum of migraine frequency converged to similar CGRP values. In contrast, in patients with concomitant depressive symptoms, this convergence did not happen. INTERPRETATION: Patients with migraine not only have higher CGRP levels compared with HCs, but also the presence of depressive symptoms seems to increase salivary CGRP levels and we have evidence, for the first time, that baseline salivary CGRP concentration is associated with treatment response to erenumab. ANN NEUROL 2022;92:846-859.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Alpuente A, Gallardo VJ, Asskour L, et al. Salivary CGRP and Erenumab Treatment Response: Towards Precision Medicine in Migraine. Ann Neurol. 2022. PMID: 36054144. doi:10.1002/ana.26472

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。